AVBP

Insider Trades

Name	Value	Action	Price	Current Price
Hillhouse Investment Management, Ltd.10 Percent Owner $13M555.6k shares SellDec 10, 2025 $23.37 --

News

seekingalpha.comArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Caseseekingalpha.comMay 16

globenewswire.comArriVent BioPharma Reports First Quarter 2026 Financial Resultsglobenewswire.comMay 11

globenewswire.comArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancersglobenewswire.comMay 7

defenseworld.netArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Moderate Buy” by Analystsdefenseworld.netApr 24

zacks.comAre You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choicezacks.comApr 15

Trade AVBP

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, advancing, and bringing to market treatments addressing critical gaps in cancer patient care. The company specifically focuses on developing and commercializing targeted oncology therapies for conditions like non-small-cell lung cancer (NSCLC) and various solid tumor indications. Among its pipeline candidates are Furmonertinib, an epidermal growth factor receptor (EGFR) mutant-selective tyrosine kinase inhibitor currently undergoing a Phase 3 clinical trial for NSCLC treatment, and ARR-002. ArriVent maintains strategic alliances, including one with Aarvik Therapeutics Inc. Established in 2021, its operations are headquartered in Newtown Square, Pennsylvania.

CEO: Zhengbin Yao
IPO Date: Jan 26, 2024

Market Data

Open: $32.70
High: $32.70
Low: $31.43
Volume: 591K
Avg Volume: 495.7K
52W High: $33.62
52W Low: $16.10

Valuation

Market Cap: $1.5B
Enterprise Value: $1.4B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-161M
Revenue: $0
Net Income: $-166M
Cash: $46M
Debt: $14k

Events

EarningsAug 10

EPS est. -0.98